Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GELESIS HOLDINGS, INC.GLS · Entity 109516 | Director | May 06, 2022 | May 09, 2022 |
| Inogen IncINGN · Entity 2083 | EVP, Finance, & CFO | December 01, 2021 | December 03, 2021 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | Director | February 15, 2023 | February 17, 2023 |
| Sight Sciences, Inc.SGHT · Entity 5537 | Chief Operating Officer | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GELESIS HOLDINGS, INC.
Report date May 06, 2022 · Filed May 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,095 |
Reported balance
After 2022-05-06 transaction · row 1
1 source rowRow 1 · 2022-05-06 · Grant · Acquired 51,095 · Balance 51,095 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2: These RSUs vest in full on March 1, 2023, subject to the reporting person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
F2: These RSUs vest in full on March 1, 2023, subject to the reporting person's continued service at such time.
Inogen Inc
Report date December 01, 2021 · Filed December 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,902 |
Last balance in matching sequence
After 2021-12-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-12-01 · Exercise / conversion · Acquired 546 · Balance 34,392 F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. Row 2 · 2021-12-01 · Tax withholding · Disposed 490 · Balance 33,902 F2: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2021. F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,915 |
Reported balance
After 2021-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-01 · Exercise / conversion · Disposed 546 · Balance 4,915 F3: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F4: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares beneficially owned are 30,155 shares more than the previously filed Form 4s due to an error reporting the shares owned on December 15, 2020. An amendment to the original Form 4 has been filed to correct the error.
F2: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a time-based restricted stock award that vested on December 1, 2021.
F3: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
F4: Subject to the reporting person's continued service, 25% of the restricted stock units shall vest on March 1, 2021, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month, subject to the reporting person continuing to be a service provider through each such vesting date.
Pear Therapeutics, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 71,428 |
Reported balance
After 2023-02-15 transaction · row 1
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 71,428 · Balance 71,428 |
Sight Sciences, Inc.
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 639,449 |
Reported balance
After 2026-10-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,260 · Balance 639,449 F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (i) 214,450 shares of Common Stock, and (ii) 424,999 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs").
F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (i) 214,450 shares of Common Stock, and (ii) 424,999 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2018 Filed Jun 13, 2018 20:08 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,898 | $180.19 | $522,179.32 |
DisclosureSEC source: 0001209191-18-037446 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,004 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 2,898 shares sold in the price range of $179.66 to $180.64 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:08 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 259 | $178.83 | $46,316.71 |
DisclosureSEC source: 0001209191-18-037446 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 259 shares sold in the price range of $178.58 to $179.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:08 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 5,000 | $0.60 | $3,000.00 |
DisclosureSEC source: 0001209191-18-037446 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2018 Filed Mar 10, 2018 01:55 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,911 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-018678 · doc4.xml · derivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,911 shares Expires 2018-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is January 1, 2008. Read SEC document |
| March 08, 2018 Filed Mar 10, 2018 01:55 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,012 | $125.84 | $127,345.32 |
DisclosureSEC source: 0001209191-18-018678 · doc4.xml · nonDerivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,161 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F4 · price: Represents the weighted average share price of an aggregate total of 1,012 shares sold in the price range of $125.7475 to $126.2100 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 10, 2018 01:55 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 4,594 | $124.88 | $573,694.59 |
DisclosureSEC source: 0001209191-18-018678 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,173 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 4,594 shares sold in the price range of $124.710 to $125.625 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 10, 2018 01:55 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 10,305 | $124.18 | $1,279,632.65 |
DisclosureSEC source: 0001209191-18-018678 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,767 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 10,305 shares sold in the price range of $123.71 to $124.63 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 10, 2018 01:55 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 15,911 | $2.40 | $38,186.40 |
DisclosureSEC source: 0001209191-18-018678 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 22:42 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 3,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017397 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,161 F1 · shares: The reported securities represent shares of restricted stock, 25% of which shall vest on March 1, 2019, and 1/16th of which shall vest every three months thereafter on the 1st day of the month, subject in each case to the reporting person remaining a service provider through each such applicable vesting date. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:49 UTC | Inogen Inc INGN · Entity 2083 | Tax withholdingCommon Stock | 464 | $118.33 | $54,905.12 |
DisclosureSEC source: 0001209191-18-015927 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883 F2 · shares: The reported shares were withheld in a net issuance to cover the Reporting Person's tax withholding liability in connection with the portion of the 2017 performance-based RSU that was earned and vested on March 1, 2018. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:49 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 1,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015927 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,347 F1 · shares: The reported securities represent shares earned and vested on March 1, 2018 based on achievement of the financial performance conditions for the 2017 fiscal year that were approved as part of the 2017 performance-based RSU granted on August 8, 2017. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 22:57 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001209191-18-013135 · doc4.xml · derivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 12,000 shares Expires 2022-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month on the same day as the vesting commencement date. The vesting commencement date for this option is May 1, 2015. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 22:57 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 700 | $132.46 | $92,721.51 |
DisclosureSEC source: 0001209191-18-013135 · doc4.xml · nonDerivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F4 · price: Represents the weighted average share price of an aggregate total of 700 shares sold in the price range of $132.060 to $132.645 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 22:57 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,600 | $131.41 | $341,675.10 |
DisclosureSEC source: 0001209191-18-013135 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 2,600 shares sold in the price range of $131.05 to $131.87 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 22:57 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 8,700 | $130.33 | $1,133,843.16 |
DisclosureSEC source: 0001209191-18-013135 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 8,700 shares sold in the price range of $130.00 to $130.91 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 22:57 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 12,000 | $38.54 | $462,480.00 |
DisclosureSEC source: 0001209191-18-013135 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,192 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001209191-18-011634 · doc4.xml · derivative · entry 7 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 3,192 shares Expires 2022-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month on the same day as the vesting commencement date. The vesting commencement date for this option is May 1, 2015. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 200 | $126.26 | $25,252.00 |
DisclosureSEC source: 0001209191-18-011634 · doc4.xml · nonDerivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,992 | $125.35 | $375,055.28 |
DisclosureSEC source: 0001209191-18-011634 · doc4.xml · nonDerivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 2,992 shares sold in the price range of $125.00 to $125.97 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 3,192 | $38.54 | $123,019.68 |
DisclosureSEC source: 0001209191-18-011634 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,808 | $0.00 Strike: $38.54 | $0.00 |
DisclosureSEC source: 0001209191-18-011634 · doc4.xml · derivative · entry 6 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,192 Underlying: Common Stock · 8,808 shares Expires 2022-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month on the same day as the vesting commencement date. The vesting commencement date for this option is May 1, 2015. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 8,808 | $125.03 | $1,101,271.29 |
DisclosureSEC source: 0001209191-18-011634 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 8,808 shares sold in the price range of $125.00 to $125.30 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 01:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 8,808 | $38.54 | $339,460.32 |
DisclosureSEC source: 0001209191-18-011634 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:17 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 1,982 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001209191-18-010927 · doc4.xml · derivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,563 Underlying: Common Stock · 1,982 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is May 1, 2016. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:17 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,982 | $120.10 | $238,028.49 |
DisclosureSEC source: 0001209191-18-010927 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 1,982 shares sold in the price range of $120.000 to $120.515 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:17 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 1,982 | $44.19 | $87,584.58 |
DisclosureSEC source: 0001209191-18-010927 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:46 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 9,737 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001209191-18-010571 · doc4.xml · derivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,545 Underlying: Common Stock · 9,737 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is May 1, 2016. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:46 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 9,737 | $120.05 | $1,168,927.82 |
DisclosureSEC source: 0001209191-18-010571 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 9,737 shares sold in the price range of $120.00 to $120.27 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 02:46 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 9,737 | $44.19 | $430,278.03 |
DisclosureSEC source: 0001209191-18-010571 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 15,912 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · derivative · entry 10 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,911 Underlying: Common Stock · 15,912 shares Expires 2018-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is January 1, 2008. F10 · derivative.expiration_date: Previously filed forms 3 and 4 reported incorrect expiration date. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,668 | $118.13 | $315,162.30 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 8 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F7 · price: Represents the weighted average share price of an aggregate total of 2,668 shares sold in the price range of $117.99 to $118.56 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 7,120 | $117.45 | $836,217.66 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 7 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,668 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F6 · price: Represents the weighted average share price of an aggregate total of 7,120 shares sold in the price range of $116.94 to $117.93 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,927 | $116.26 | $340,293.31 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 6 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F5 · price: Represents the weighted average share price of an aggregate total of 2,927 shares sold in the price range of $115.940 to $116.655 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 3,197 | $115.25 | $368,442.42 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,715 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F4 · price: Represents the weighted average share price of an aggregate total of 3,197 shares sold in the price range of $114.66 to $115.61 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 15,912 | $2.40 | $38,188.80 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 11,718 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · derivative · entry 9 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,282 Underlying: Common Stock · 11,718 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Subject to the reporting person's continuing service, twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the vesting commencement date, and thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is May 1, 2016. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 3,505 | $116.42 | $408,058.41 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 3,505 shares sold in the price range of $116.105 to $117.060 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 8,213 | $115.63 | $949,693.01 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,505 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 8,213 shares sold in the price range of $115.100 to $116.095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:11 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 11,718 | $44.19 | $517,818.42 |
DisclosureSEC source: 0001209191-18-009717 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:01 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 6,550 | $95.95 | $628,444.34 |
DisclosureSEC source: 0001209191-17-056717 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F4 · price: Represents the weighted average share price of an aggregate total of 6,550 shares sold in the price range of $95.66 to $96.56 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:01 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 3,016 | $94.80 | $285,918.01 |
DisclosureSEC source: 0001209191-17-056717 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,550 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F3 · price: Represents the weighted average share price of an aggregate total of 3,016 shares sold in the price range of $94.39 to $95.22 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:01 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 5,434 | $93.78 | $509,591.28 |
DisclosureSEC source: 0001209191-17-056717 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F2 · price: Represents the weighted average share price of an aggregate total of 5,434 shares sold in the price range of $93.29 to $94.28 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 20:54 UTC | Inogen Inc INGN · Entity 2083 | GrantRestricted Stock Units · Derivative | 4,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049003 · doc4.xml · derivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,043 Underlying: Common Stock · 4,043 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Inogen common stock. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on September 1, 2018, and 1/16th of the restricted stock units shall vest every three months thereafter on the 1st day of the month. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 22:16 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 6,667 | $92.64 | $617,616.88 |
DisclosureSEC source: 0001209191-17-048661 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F2 · price: Represents the weighted average share price of an aggregate total of 6,667 shares sold in the price range of $92.2901 to $92.8800 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 12, 2017 17:30 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 400 | $87.25 | $34,899.00 |
DisclosureSEC source: 0001209191-17-031804 · doc4.xml · nonDerivative · entry 5 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,667 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F6 · price: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $87.15 to $87.40 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 12, 2017 17:30 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,413 | $84.73 | $119,719.39 |
DisclosureSEC source: 0001209191-17-031804 · doc4.xml · nonDerivative · entry 4 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,067 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F5 · price: Represents the weighted average share price of an aggregate total of 1413 shares sold in the price range of $84.43 to $85.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 12, 2017 17:30 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,402 | $83.71 | $117,355.95 |
DisclosureSEC source: 0001209191-17-031804 · doc4.xml · nonDerivative · entry 3 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,480 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F4 · price: Represents the weighted average share price of an aggregate total of 1402 shares sold in the price range of $83.38 to $83.99 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 12, 2017 17:30 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 876 | $82.64 | $72,390.80 |
DisclosureSEC source: 0001209191-17-031804 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,882 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F3 · price: Represents the weighted average share price of an aggregate total of 876 shares sold in the price range of $82.30 to $83.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2017 Filed May 12, 2017 17:30 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,575 | $81.75 | $210,499.04 |
DisclosureSEC source: 0001209191-17-031804 · doc4.xml · nonDerivative · entry 1 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,758 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F2 · price: Represents the weighted average share price of an aggregate total of 2575 shares sold in the price range of $81.280 to $82.235 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:41 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 710 | $67.61 | $48,004.73 |
DisclosureSEC source: 0001209191-17-010602 · doc4.xml · nonDerivative · entry 2 Bauerlein Alison · CIK 0001596080 · EVP, Finance, & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2016. F3 · price: Represents the weighted average share price of an aggregate total of 710 shares sold in the price range of $67.47 to $67.67 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.